Das zweite Primärmalignom beim Krebspatienten – Epidemiologie, Prognose und klinische Relevanz

R. T. Grundmann; F. Meyer

doi:10.1055/s-0031-1283939

Zentralblatt für Chirurgie, Table of Contents

Zentralbl Chir 2012; 137(6): 565-574
DOI: 10.1055/s-0031-1283939

Übersicht

Das zweite Primärmalignom beim Krebspatienten – Epidemiologie, Prognose und klinische Relevanz

Second Primary Malignancy among Cancer Survivors – Epidemiology, Prognosis and Clinical Relevance

Authors

R. T. Grundmann

¹In den Grüben 144, Burghausen, Deutschland, www.medsachverstand.de
F. Meyer

²Universitätsklinikum Magdeburg A. ö. R., Klinik für Allgemein-, Viszeral- & Gefäßchirurgie, Magdeburg, Deutschland

Abstract

Zusammenfassung

Hintergrund: Ansteigendes Alter der Bevölkerung sowie Fortschritte in der Therapie und damit ein verbessertes Überleben von Patienten mit Tumorerkrankungen haben dazu geführt, dass häufiger bei Überlebenden einer Krebsbehandlung im weiteren Verlauf ein zweiter maligner Primärtumor beobachtet wird. Die Konsequenzen sollen in dieser Übersicht dargestellt werden.

Methodik: Für die Literaturübersicht wurde die Datenbank Medline (PubMed) unter den Schlüsselwörtern „Multiple primary malignant tumors“ sowie „(Neoplasms, second primary) AND "Neoplasms, Second Primary"[Mesh]“ durchsucht. Es wurden primär Veröffentlichungen der letzten 7 Jahre (2005 – 2011) abgefragt.

Ergebnisse: Die Prävalenz an Patienten mit Zweitmalignomen wird in verschiedenen Krebsregistern mit 6,6 % bis 9 % angegeben. Dabei ist das Malignomrisiko des Krebspatienten, abhängig vom Alter, im Vergleich zu dem der Allgemeinbevölkerung wenigstens um 20 % erhöht, bei Überlebenden einer kindlichen Krebstherapie beträgt das Zweitmalignomrisiko sogar das 3 – 6-Fache. Die Inzidenz der Zweitmalignome ist entscheidend von der Prognose des Ersttumors abhängig: Bei Patienten mit prognostisch ungünstigen Karzinomen wie Pankreas- oder Magenkarzinom werden 15 Jahre nach Erstdiagnose bei weniger als 5 % der Patienten Zweitmalignome entdeckt, hingegen beträgt die Rate bei Patienten mit kolorektalem Karzinom oder Schilddrüsenkarzinom nach 25 Jahren ca. 15 %.

Schlussfolgerung: Auswirkungen aus diesen Daten ergeben sich für die Primärdiagnostik, die bei Karzinomen mit gehäufter Inzidenz synchroner Zweitkarzinome nach entsprechenden Tumoren vor Beginn der Therapie suchen muss. Beispiele sind das synchrone Kolon-Zweitkarzinom oder Karzinome in Mund und Rachen bei Patienten mit Speiseröhrenkarzinom. Eine weitere Konsequenz stellt ein gezieltes Follow-up bei entsprechenden Risikopopulationen dar. Hierzu gehört das Screening auf metachrone kolorektale Zweitkarzinome, der Ausschluss von gastrointestinalen Zweitmalignomen bei Patienten mit GIST oder das Brustkrebs-Screening bei jungen Patientinnen mit Schilddrüsenmalignom. Da eine Radiotherapie die Rate an Zweitmalignomen erhöht, sollte eine adjuvante Strahlentherapie gut begründet werden. Dies gilt allerdings nur für jüngere Patienten, das strahlenbedingte Zweitmalignomrisiko des älteren Patienten ist gering.

Abstract

Background: Rising population age and advances in treatment with improved survival from cancer have led to more frequent survivors of cancer treatment and subsequently to more patients with a second primary tumour. The consequences are presented in this overview.

Method: For the literature review, the Medline database (PubMed) was searched under the key words “multiple primary malignant tumors” and “(Neoplasms, second primary) AND "Neoplasms, Second Primary"[Mesh]”. Primarily, publications in the last 7 years (2005 – 2011) were sought.

Results: The prevalence of patients with second primary cancer is reported in various cancer registries with 6.6 % to 9 %. Here, the risk of developing new primary cancer in cancer survivors, depending on age, compared to the general population is increased at least by 20 %. Among childhood cancer survivors, the risk was even 3 – to 6-times higher than would have been expected in the general population. The incidence of second malignant neoplasms is crucially dependent on the prognosis of the first tumour. Fifteen years after initial diagnosis, in patients with prognostically unfavourable tumours such as pancreatic or gastric carcinoma, second primary malignancies are detected in less than 5 %. However, the cumulative incidence of all second cancers combined is approximately 15 % at 25 years in patients with colorectal or thyroid cancer.

Conclusion: Implications from these data arise for primary diagnostics which must look at cancers with frequent synchronous second malignancies for respective tumours before treatment. Examples are synchronous colorectal lesions in patients with colorectal carcinoma or synchronous cancers of the oral cavity and pharynx in patients with oesophageal carcinoma. Another consequence is a targeted follow-up of corresponding risk populations. This includes the screening for metachronous colorectal cancer, the exclusion of gastrointestinal second malignancies in patients with GIST, or the breast cancer screening in young female thyroid cancer survivors. Since radiotherapy increases the rate of second primary neoplasms, adjuvant radiotherapy should be well justified. Nevertheless, this is true only for young patients, mainly in childhood. The risk of a second cancer after irradiation in adults is small.

Schlüsselwörter

multiple primäre Malignome - Zweitmalignom - Häufigkeit - Prognose - Therapie

Key words

multiple primary malignancies - second primary neoplasms - frequency - prognosis - treatment

Full Text

References

Literatur
1 Travis LB, Rabkin CS, Brown LM et al. Cancer survivorship – genetic susceptibility second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25
2 López ML, Lana A, Díaz S et al. Multiple primary cancer: an increasing health problem. Strategies for prevention in cancer survivors. Eur J Cancer Care (Engl) 2009; 18: 598-605
3 Tillack A. Zum Risiko eines Zweitmalignoms bei Krebskranken anhand der Daten des klinischen Krebsregisters des Tumorzentrums Land Brandenburg. [Dissertation] Berlin: Medizinische Fakultät Charité – Universitätsmedizin Berlin; 2009
4 Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and statistical study. Am J Cancer 1932; 16: 1358-1414
5 Curtis RE, Freedman DM, Ron E. et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute; 07.09.2011 http://seer.cancer.gov/publications/mpmono/ NIH Publ. No. 05-5302. Bethesda, MD, 2006
6 Liu L, de Vries E, Louwman M et al. Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer 2011; 128: 1659-1667
7 Dong C, Hemminki K. Second primary neoplasms in 633 964 cancer patients in Sweden, 1958–1996. Int J Cancer 2001; 93: 155-161
8 Mariotto AB, Rowland JH, Ries LA et al. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007; 16: 566-571
9 Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008; 14: 429-434
10 Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol 2009; 471: 85-105
11 Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011; 11: 83-83
12 van Gaal JC, Bastiaannet E, Schaapveld M et al. Cancer in adolescents and young adults in north Netherlands (1989–2003): increased incidence, stable survival and high incidence of second primary tumours. Ann Oncol 2009; 20: 365-373
13 Park SM, Lim MK, Jung KW et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007; 25: 4835-4843
14 Luciani A, Ascione G, Marussi D et al. Clinical analysis of multiple primary malignancies in the elderly. Med Oncol 2009; 26: 27-31
15 Wright JD, St Clair CM, Deutsch I et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010; 116: 2486-2492
16 Berrington de Gonzalez A, Curtis RE, Kry SF et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12: 353-360
17 Moon K, Stukenborg GJ, Keim J et al. Cancer incidence after localized therapy for prostate cancer. Cancer 2006; 107: 991-998
18 Rapiti E, Fioretta G, Verkooijen HM et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 2008; 123: 1141-1145
19 Huo D, Hetzel JT, Roy H et al. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev 2009; 18: 1979-1985
20 Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol 2007; 30: 333-339
21 Strassburg J, Ruppert R, Ptok H et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol 2011; 18: 2790-2799
22 Birgisson H, Påhlman L, Gunnarsson U et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005; 23: 6126-6131
23 Wilson CL, Cohn RJ, Johnston KA et al. Late mortality and second cancers in an Australian cohort of childhood cancer survivors. Med J Aust 2010; 193: 258-261
24 Armstrong GT, Liu Q, Yasui Y et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338
25 Meadows AT, Friedman DL, Neglia JP et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356-2362
26 Taylor AJ, Croft AP, Palace AM et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer 2009; 125: 2400-2405
27 Reulen RC, Frobisher C, Winter DL et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011; 305: 2311-2319
28 Olsen JH, Möller T, Anderson H et al. Lifelong cancer incidence in 47 697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009; 101: 806-813
29 Friedman DL, Whitton J, Leisenring W et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083-1095
30 Tukenova M, Diallo I, Hawkins M et al. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment. Cancer Epidemiol Biomarkers Prev 2010; 19: 707-715
31 Dores GM, Anderson WF, Beane Freeman LE et al. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin’s lymphoma treated with radiotherapy. Br J Cancer 2010; 103: 1081-1084
32 Howell SJ, Searle C, Goode V et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009; 101: 582-588
33 Nathan PC, Ness KK, Mahoney MC et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med 2010; 153: 442-451
34 Levi F, Randimbison L, Maspoli M et al. Second neoplasms after oesophageal cancer. Int J Cancer 2007; 121: 694-697
35 Chuang SC, Hashibe M, Scelo G et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev 2008; 17: 1543-1549
36 Sato Y, Motoyama S, Maruyama K et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg 2005; 201: 188-193
37 Bamba T, Kosugi S, Takeuchi M et al. Surveillance and treatment for second primary cancer in the gastric tube after radical esophagectomy. Surg Endosc 2010; 24: 1310-1317
38 Lee JH, Bae JS, Ryu KW et al. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol 2006; 12: 2588-2592
39 Wu CW, Lo SS, Chen JH et al. Multiple primary cancers in patients with gastric cancer. Hepatogastroenterology 2006; 53: 463-467
40 Park DI, Park SH, Yoo TW et al. The prevalence of colorectal neoplasia in patients with gastric cancer: a Korean Association for the Study of Intestinal Disease (KASID) Study. J Clin Gastroenterol 2010; 44: 102-105
41 Muela Molinero A, Jorquera Plaza F, Ribas Ariño T et al. Multiple malignant primary neoplasms in patients with gastric neoplasms in the health district of León. Rev Esp Enferm Dig 2006; 98: 907-916
42 Saito S, Hosoya Y, Togashi K et al. Prevalence of synchronous colorectal neoplasms detected by colonoscopy in patients with gastric cancer. Surg Today 2008; 38: 20-25
43 Eom BW, Lee HJ, Yoo MW et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol 2008; 98: 106-110
44 Ha TK, An JY, Youn HG et al. Surgical outcome of synchronous second primary cancer in patients with gastric cancer. Yonsei Med J 2007; 48: 981-987
45 Nishikawa M, Higashino M, Tanimura S et al. Three cases of synchronous laparoscopic resection for gastric and colonic cancer. Surg Laparosc Endosc Percutan Tech 2010; 20: e218-e225
46 Tokunaga M, Hiki N, Fukunaga T et al. Laparoscopic surgery for synchronous gastric and colorectal cancer: a preliminary experience. Langenbecks Arch Surg 2010; 395: 207-210
47 Lee J, Nam Y, Kim W. Simultaneous laparoscopy-assisted distal gastrectomy and right hemicolectomy for synchronous advanced gastric and colon cancer. Surg Laparosc Endosc Percutan Tech 2010; 20: 257-261
48 Scélo G, Boffetta P, Hemminki K et al. Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118: 189-196
49 Zar N, Garmo H, Holmberg L et al. Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer 2008; 44: 718-725
50 Kim MS, Park YJ. Detection and treatment of synchronous lesions in colorectal cancer: the clinical implication of perioperative colonoscopy. World J Gastroenterol 2007; 13: 4108-4111
51 Achiam MP, Burgdorf SK, Wilhelmsen M et al. Inadequate preoperative colonic evaluation for synchronous colorectal cancer. Scand J Surg 2009; 98: 62-67
52 Cai H, Dong RZ, Wu JH et al. [Clinical analysis of 168 cases of multiple primary colorectal carcinoma]. Zhonghua Wai Ke Za Zhi 2008; 46: 370-374
53 Ringland CL, Arkenau HT, O’Connell DL et al. Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. Ann Oncol 2010; 21: 92-97
54 Das A, Chak A, Cooper GS. Temporal trend in relative risk of second primary colorectal cancer. Am J Gastroenterol 2006; 101: 1342-1347
55 Bouvier AM, Latournerie M, Jooste V et al. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer 2008; 44: 522-527
56 Gervaz P, Bucher P, Neyroud-Caspar I et al. Proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer: a population-based study. Dis Colon Rectum 2005; 48: 227-232
57 Ahmed F, Goodman MT, Kosary C et al. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer 2006; 107 (Suppl. 05) 1162-1171
58 Noura S, Ohue M, Seki Y et al. Second primary cancer in patients with colorectal cancer after a curative resection. Dig Surg 2009; 26: 400-405
59 Yamamoto S, Yoshimura K, Ri S et al. The risk of multiple primary malignancies with colorectal carcinoma. Dis Colon Rectum 2006; 49 (Suppl. 10) 30-36
60 Lee WS, Lee JN, Choi S et al. Multiple primary malignancies involving colorectal cancer – clinical characteristics and prognosis with reference to surveillance. Langenbecks Arch Surg 2010; 395: 359-364
61 Agaimy A, Wünsch PH, Sobin LH et al. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006; 23: 120-129
62 Ponti G, Luppi G, Martorana D et al. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep 2010; 23: 437-444
63 Pandurengan RK, Dumont AG, Araujo DM et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010; 21: 2107-2111
64 Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. World J Gastrointest Surg 2010; 2: 314-318
65 Baumgaertner I, Corcos O, Couvelard A et al. Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study. Am J Gastroenterol 2008; 103: 2878-2882
66 Choi MG, Kim SW, Han SS et al. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg 2006; 141: 51-56
67 Yoon WJ, Ryu JK, Lee JK et al. Extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated factors, and comparison with patients with other pancreatic cystic neoplasms. Ann Surg Oncol 2008; 15: 3193-3198
68 Riall TS, Stager VM, Nealon WH et al. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg 2007; 204: 803-813
69 Reid-Lombardo KM, Mathis KL, Wood CM et al. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg 2010; 251: 64-69
70 Subramanian S, Goldstein DP, Parlea L et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17: 1277-1288
71 Omür O, Ozcan Z, Yazici B et al. Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocr J 2008; 55: 365-372
72 Verkooijen RB, Smit JW, Romijn JA et al. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 2006; 155: 801-806
73 Sawka AM, Thabane L, Parlea L et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19: 451-457
74 Brown AP, Chen J, Hitchcock YJ et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93: 504-515
75 Fallahi B, Adabi K, Majidi M et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med 2011; 36: 277-282
76 Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 2006; 115: 607-610
77 Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 2006; 163: 521-527
78 Kohlmann W, Gruber SB. Lynch Syndrome. In: Pagon RA, Bird TD, Dolan CR. et al. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2011 07.09.2011. http://www.ncbi.nlm.nih.gov/books/NBK1211/
79 Delman KA, Shapiro SE, Jonasch EW et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg 2006; 30: 665-669
80 Blansfield JA, Choyke L, Morita SY et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142: 814-818
81 Safo AO, Pambuccian SE. Pancreatic manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med 2010; 134: 1080-1083
82 Ruijs MW, Verhoef S, Rookus MA et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47: 421-428
83 Ognjanovic S, Oliver M, Bergemann TL et al. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 2012; 118: 1387-1396
84 Izawa N, Matsumoto S, Manabe J et al. A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene. Int J Clin Oncol 2008; 13: 78-82
85 Friedman JM. Neurofibromatosis 1. In: Pagon RA, Bird TD, Dolan CR. et al. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2011 07.09.2011. http://www.ncbi.nlm.nih.gov/books/NBK1109/
86 Miettinen M, Fetsch JF, Sobin LH et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90-96
87 Rosso S, De Angelis R, Ciccolallo L et al. Multiple tumours in survival estimates. Eur J Cancer 2009; 45: 1080-1094
88 Ellison LF. Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry. Cancer Epidemiol 2010; 34: 550-555
89 Lana Pérez A, Folgueras Sánchez MV, Díaz Rodríguez S et al. [Survival analysis in multiple cancer patients in Asturias, Spain, 1975–2004]. Rev Esp Salud Publica 2008; 82: 167-177
90 Gotay CC, Ransom S, Pagano IS. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer 2007; 110: 2101-2109